CBIO · Crescent Biopharma Inc
United States · RS rating 26 · As of 2026-10-14
| Price | 12.58 USD |
|---|---|
| 1-day change | -2.6% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 5 / 22 / 77 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 24 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -215.8% |
| Sales growth Q/Q | -90.4% |
| Distance from 52-week high | +53.4% |
| Market cap (USD) | $782.9M |